|
UNITED STATES |
|
|
SECURITIES AND EXCHANGE COMMISSION |
|
|
Washington, D.C. 20549 |
|
|
|
|
|
FORM 8-K |
|
|
|
|
|
CURRENT REPORT |
|
|
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 |
|
|
|
|
|
Date of Report (Date of earliest event reported): October 25, 2004 |
|
|
|
|
|
VERTEX PHARMACEUTICALS INCORPORATED |
|
|
(Exact name of registrant as specified in its charter) |
|
|
|
|
|
MASSACHUSETTS |
000-19319 |
04-3039129 |
|
(State
or other jurisdiction |
(Commission |
(IRS
Employer |
|
|
|
|
|
|
|
130 Waverly Street |
|
|
|
|
Cambridge, Massachusetts |
02139 |
|
|
|
(Address of principal executive offices) |
(Zip Code) |
|
|
|
|
(617) 444-6100 |
|
Registrant’s telephone number, including area code: |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Disclosure of Results of Operations and Financial Condition.
On October 25, 2004, Vertex Pharmaceuticals Incorporated issued a press release that reports its consolidated financial results for the quarter ended September 30, 2004 and provides an update on selected clinical developments during the same period.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
|
(c) Exhibits |
|
|||
|
|
|
|||
|
|
Exhibit |
|
Description of Document |
|
|
|
|
|||
|
|
99.1 |
|
Press Release of Vertex Pharmaceuticals Incorporated, dated October 25, 2004, entitled “Vertex Pharmaceuticals Reports Third Quarter 2004 Financial Results and Provides Clinical Update”. |
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
VERTEX PHARMACEUTICALS INCORPORATED |
|
|
(Registrant) |
|
|
|
|
|
|
|
Date: October 25, 2004 |
/s/ Ian F. Smith |
|
|
Ian F. Smith |
|
|
Senior Vice President and Chief Financial Officer |
2